Revelation Biosciences REVB Stock
Revelation Biosciences Price Chart
Revelation Biosciences REVB Financial and Trading Overview
| Revelation Biosciences stock price | 3.79 USD |
| Previous Close | 3.68 USD |
| Open | 3.76 USD |
| Bid | 0.58 USD x 200 |
| Ask | 1 USD x 200 |
| Day's Range | 3.66 - 3.88 USD |
| 52 Week Range | 3.08 - 40.6 USD |
| Volume | 16.22K USD |
| Avg. Volume | 10.12K USD |
| Market Cap | 2.16M USD |
| Beta (5Y Monthly) | -0.06 |
| PE Ratio (TTM) | 0.117373794 |
| EPS (TTM) | 32.29 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 124.25 USD |
REVB Valuation Measures
| Enterprise Value | -8586142 USD |
| Trailing P/E | 0.117373794 |
| Forward P/E | -0.18734553 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.2102052 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.764 |
Trading Information
Revelation Biosciences Stock Price History
| Beta (5Y Monthly) | -0.06 |
| 52-Week Change | -89.50% |
| S&P500 52-Week Change | 10.88% |
| 52 Week High | 40.6 USD |
| 52 Week Low | 3.08 USD |
| 50-Day Moving Average | 6.16 USD |
| 200-Day Moving Average | 8.69 USD |
REVB Share Statistics
| Avg. Volume (3 month) | 10.12K USD |
| Avg. Daily Volume (10-Days) | 37.35K USD |
| Shares Outstanding | 569.06K |
| Float | 435.2K |
| Short Ratio | 0.06 |
| % Held by Insiders | 10.27% |
| % Held by Institutions | 10.73% |
| Shares Short | 225 |
| Short % of Float | 0.040% |
| Short % of Shares Outstanding | 0.040% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:7 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -78.72% |
| Return on Equity (ttm) | -154.76% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -11241206 USD |
| Net Income Avi to Common (ttm) | -19201976 USD |
| Diluted EPS (ttm) | 32.29 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.48M USD |
| Total Cash Per Share (mrq) | 20.18 USD |
| Total Debt (mrq) | 739.92K USD |
| Total Debt/Equity (mrq) | 7.35 USD |
| Current Ratio (mrq) | 6.214 |
| Book Value Per Share (mrq) | 18.03 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -9327937 USD |
| Levered Free Cash Flow (ttm) | -5777208 USD |
Profile of Revelation Biosciences
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 4660 La Jolla Village Drive |
| ZIP | 92122 |
| Phone | 650 800 3717 |
| Website | https://www.revbiosciences.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 8 |
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Q&A For Revelation Biosciences Stock
What is a current REVB stock price?
Revelation Biosciences REVB stock price today per share is 3.79 USD.
How to purchase Revelation Biosciences stock?
You can buy REVB shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Revelation Biosciences?
The stock symbol or ticker of Revelation Biosciences is REVB.
Which industry does the Revelation Biosciences company belong to?
The Revelation Biosciences industry is Biotechnology.
How many shares does Revelation Biosciences have in circulation?
The max supply of Revelation Biosciences shares is 569.06K.
What is Revelation Biosciences Price to Earnings Ratio (PE Ratio)?
Revelation Biosciences PE Ratio is 0.11737379 now.
What was Revelation Biosciences earnings per share over the trailing 12 months (TTM)?
Revelation Biosciences EPS is 32.29 USD over the trailing 12 months.
Which sector does the Revelation Biosciences company belong to?
The Revelation Biosciences sector is Healthcare.
Revelation Biosciences REVB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25955.34 USD — |
-0.21
|
5.73B USD — | 25866.15 USD — | 26111.62 USD — | — - | 5.73B USD — |
|
US Tech Health Care
IXHC
US
|
1327.92 USD — |
-0.97
|
— — | 1320.94 USD — | 1335.06 USD — | — - | — — |
- {{ link.label }} {{link}}
